EyePoint Pharmaceuticals, Inc. Common Stock
EYPTEyePoint Pharmaceuticals, Inc. (EYPT) is a pharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in treatments for retinal diseases, uveitis, and other ocular conditions, leveraging its expertise in drug delivery and molecular innovation to address unmet medical needs in ophthalmology.
Company News
EyePoint received a positive recommendation from its Data Safety Monitoring Committee for ongoing Phase 3 trials of DURAVYU, a potential treatment for wet age-related macular degeneration. The trials remain on track, with topline data expected in mid-2026.
EyePoint Pharmaceuticals announced a proposed public offering of $100 million in common stock to advance the clinical development of its lead product candidate DURAVYU for wet age-related macular degeneration and diabetic macular edema, as well as support its earlier stage pipeline.
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
EyePoint's stock is on track for its biggest ever one-day percentage gain in heavy volume.
The company reported positive trial data for its lead therapy to treat two different eye conditions.
